Resmed Inc (RMD) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

RMD ranks #562 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

890 institutions disclose a position in RMD, but none treat it as a major bet — even Giverny Capital Inc., its most concentrated holder, allocates just 2.5% of its own portfolio to it.

Arrowstreet Capital, Limited Partnership has added to its RMD position for two straight quarters, increasing it by $154.3M to reach $220.2M today.

BlackRock has trimmed its RMD position for two straight quarters, cutting it by $574.0M while still holding $2.4B.

RMD is up 1.9% today, and institutions have been net buyers of $6.5B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

RMD posted net income of $1.5B over the trailing twelve months, and currently trades at a P/E of 23.0.

• Profitable — net income of $1.5B over the trailing twelve months
• Revenue grew 9.9% year over year
• Net income improved year over year, from $1.4B to $1.5B
• Generated $1.8B in positive operating cash flow
• Current ratio of 3.10x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.36x equity — within a conventional range